Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients.

Authors

Selena Y Lin, Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USAFollow
Javier I J Orozco, Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USAFollow
Dave S B Hoon, Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USAFollow

Document Type

Article

Publication Date

1-1-2018

Publication Title

Advances in experimental medicine and biology

Keywords

Biomarkers; Breast cancer; CTCs; DTCs; Liquid biopsy; MRD; Melanoma; Micrometastases; cfDNA; cfmiR

Abstract

Melanoma and breast cancer (BC) patients face a high risk of recurrence and disease progression after curative surgery and/or therapeutic treatment. Monitoring for minimal residual disease (MRD) during a disease-free follow-up period would greatly improve patient outcomes through earlier detection of relapse or treatment resistance. However, MRD monitoring in solid tumors such as melanoma and BC are not well established. Here, we discuss the clinical applications of MRD monitoring in melanoma and BC patients and highlight the current approaches for detecting MRD in these solid tumors.

Clinical Institute

Cancer

Clinical Institute

Women & Children

Department

Oncology

Recommended Citation

Lin, Selena Y; Orozco, Javier I J; and Hoon, Dave S B, "Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients." (2018). Articles, Abstracts, and Reports. 947.
https://digitalcommons.providence.org/publications/947